Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
GHRS | US
0.05
0.31%
Healthcare
Biotechnology
30/06/2024
09/03/2026
15.98
15.95
16.10
15.32
GH Research PLC a clinical-stage biopharmaceutical company engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-NN-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001 an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002 an intravenous mebufotenin product candidate; and GH003 an intranasal mebufotenin product candidate which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin Ireland.
View LessStrength based on increasing price with high volume
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
68.8%1 month
60.7%3 months
93.0%6 months
81.8%-
-
2.10
0.00
0.00
-11.97
-
-
-45.53M
831.41M
831.41M
-
-
-
-
-16.20
35.79
10.82
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.84
Range1M
2.25
Range3M
6.96
Rel. volume
1.72
Price X volume
5.34M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Savara Inc | SVRA | Biotechnology | 5.43 | 893.78M | 3.04% | n/a | 26.18% |
| Arbutus Biopharma Corporation | ABUS | Biotechnology | 4.72 | 891.05M | 4.19% | n/a | 6.09% |
| SPRY | SPRY | Biotechnology | 9.05 | 877.32M | -0.11% | n/a | 0.07% |
| uniQure N.V | QURE | Biotechnology | 17.99 | 876.07M | 26.07% | n/a | 550.36% |
| Valneva SE | VALN | Biotechnology | 10.5001 | 851.31M | -0.19% | n/a | 126.08% |
| Trevi Therapeutics Inc | TRVI | Biotechnology | 11.7 | 849.33M | -12.03% | n/a | 1.80% |
| EyePoint Pharmaceuticals Inc | EYPT | Biotechnology | 15.67 | 838.63M | -0.51% | n/a | 10.20% |
| UroGen Pharma Ltd | URGN | Biotechnology | 19.91 | 838.49M | -2.69% | n/a | 326.69% |
| Xeris Pharmaceuticals Inc | XERS | Biotechnology | 5.6 | 834.39M | -3.61% | n/a | -1398.96% |
| Xencor Inc | XNCR | Biotechnology | 11.87 | 830.04M | 4.86% | n/a | 15.54% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Janus International Group Inc. | JBI | Building Products & Equipment | 5.39 | 783.29M | 1.89% | 11.62 | 116.21% |
| Latham Group Inc. | SWIM | Building Products & Equipment | 6.31 | 729.29M | 0.16% | 65.18 | 77.00% |
| Fox Factory Holding Corp | FOXF | Recreational Vehicles | 16.37 | 682.35M | 0.37% | 42.05 | 64.69% |
| Ennis Inc | EBF | Building Products & Equipment | 21.16 | 550.24M | -0.70% | 13.28 | 2.28% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 25.67 | 513.16M | -0.39% | n/a | 1.50% |
| ACCO Brands Corporation | ACCO | Building Products & Equipment | 3.67 | 351.58M | -6.14% | n/a | 174.23% |
| Camping World Holdings Inc | CWH | Recreational Vehicles | 7.47 | 337.11M | 1.49% | n/a | 3644.76% |
| MCBC Holdings Inc | MCFT | Recreational Vehicles | 19.38 | 321.85M | -1.77% | 34.27 | 26.82% |
| Marine Products Corporation | MPX | Recreational Vehicles | 7.01 | 243.37M | -1.13% | 13.23 | 0.00% |
| CPI Card Group Inc | PMTS | Building Products & Equipment | 15.485 | 172.78M | -0.23% | 15.61 | -621.78% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -11.97 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.10 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 92.95 | 72.80 | Riskier |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 831.41M | 3.66B | Emerging |